(XL184-306) A Phase 3, Randomized, Double-Blind, Controlled Trial of Cabozantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-Resistant Prostate Cancer
Description: 

The purpose of this study is to evaluate the safety and efficacy of cabozantinib to reduce pain in this patient group compared to mitoxantrone plus prednisone. Eligible patients will be randomly assigned to one of the above treatment arms. Patients will return to the clinic every 3 weeks for the IV infusion treatment and safety assessments. Patients will self report pain information by answering a health related quality of life survey by automated phone system. The estimated time of participation on this study is 12 months.

Study Number: 

PH 207911

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01522443

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.